• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bernstein initiated coverage on Cronos Group with a new price target

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email
    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00
    Get the next $CRON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    1/27/2022$5.54 → $3.24Underperform → Hold
    Jefferies
    More analyst ratings

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rudyk James Daniel

    4 - Cronos Group Inc. (0001656472) (Issuer)

    8/11/25 5:43:32 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Adler Jason Marc

    4 - Cronos Group Inc. (0001656472) (Issuer)

    8/11/25 5:42:03 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Garnick Murray R

    4 - Cronos Group Inc. (0001656472) (Issuer)

    8/11/25 5:38:54 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025

    TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 second quarter earnings conference call on Thursday, August 7, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/25/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    High Tide Closes on $30 Million Convertible Debt from Cronos Group Inc.

    CALGARY, AB, and TORONTO, ON, July 16, 2025 /PRNewswire/ - High Tide Inc. ("High Tide") (NASDAQ:HITI) (TSXV:HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it has closed a loan agreement (the "Loan Agreement") with a wholly owned subsidiary of Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) to secure convertible debt with a principal amount of $30 million (the "Junior Secured Loan"). High Tide intends to use this working capital to fund future acquisitions and organic growth as

    7/16/25 4:01:00 PM ET
    $CRON
    $HITI
    Medicinal Chemicals and Botanical Products
    Health Care
    Other Specialty Stores
    Consumer Discretionary

    Cronos Grows its International Footprint in Switzerland

    TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through its partnership with Dascoli Pharma AG ("Dascoli"), a Swiss-based company specializing in the supply and distribution of medical cannabis and healthcare training. "We are excited to partner with Dascoli to bring high-quality medical cannabis to Swiss patients," said Mike Gorenstein, Chairman, President and CEO, Cronos. "This partnership aligns with our mission to provide borderless cannabis products to European medical markets. Expanding our presence

    7/2/25 8:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    SEC Filings

    View All

    Cronos Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    8/7/25 7:41:32 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    8/7/25 7:31:56 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SD filed by Cronos Group Inc.

    SD - Cronos Group Inc. (0001656472) (Filer)

    6/2/25 8:36:56 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by CIBC

    CIBC upgraded Cronos Group from Neutral to Sector Outperform

    5/11/22 7:33:42 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025

    TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 second quarter earnings conference call on Thursday, August 7, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/25/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

    TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

    4/24/25 8:00:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

    TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/24/25 4:45:45 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    3/19/25 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

    TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

    7/22/24 4:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care